Vmbook Online ordering

Biotechnology

DARA, or Daré Bioscience, is a clinical-stage biotechnology business that creates novel treatments for gynecological diseases. DARA Bioscience's lead product candidate is Ovaprene, a non-hormonal monthly contraception product; the business is also creating medicines to treat cervical cancer, endometriosis, and vulvodynia.

Daré Bioscience was founded in 2015, became a publicly traded company in December 2020, and has its headquarters in San Diego, California.

Daré Bioscience's current market capitalization is 108.16 million USD.

The business posted a net loss in the third quarter of 2022 of $6.8 million compared to $3.4 million in the third quarter of 2021. In the third quarter of 2022, research and development expenses increased to approximately $4.1 million compared to $1.7 million in the third quarter of 2021.

The company has not turned a profit yet, but it continues to develop new medicines and expand its product portfolio, and its lead product candidate, Ovaprene, is undergoing Phase 3 trials.

Daré Bioscience's stock price has been volatile, like many biotechnology firms; however, it has the potential for significant growth if its medicines continue to advance through clinical trials and prove effective. The company's principal focus is on expanding its product offerings and moving current candidates through clinical trials, with the ultimate intention of bringing novel medicines to market.

Finally, while there is uncertainty around biotechnology stocks, Daré Bioscience has great development possibilities in the women's health industry, with a promising product pipeline. Investors must conduct thorough research and assess risk tolerance before investing in a firm like Daré Bioscience.